126 related articles for article (PubMed ID: 38866914)
1. Elevated fecal calprotectin is associated with gut microbial dysbiosis, altered serum markers and clinical outcomes in older individuals.
Heinzel S; Jureczek J; Kainulainen V; Nieminen AI; Suenkel U; von Thaler AK; Kaleta C; Eschweiler GW; Brockmann K; Aho VTE; Auvinen P; Maetzler W; Berg D; Scheperjans F
Sci Rep; 2024 Jun; 14(1):13513. PubMed ID: 38866914
[TBL] [Abstract][Full Text] [Related]
2. A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin.
Klingberg E; Magnusson MK; Strid H; Deminger A; Ståhl A; Sundin J; Simrén M; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2019 Nov; 21(1):248. PubMed ID: 31771630
[TBL] [Abstract][Full Text] [Related]
3. Development of an Index Score for Intestinal Inflammation-Associated Dysbiosis Using Real-World Stool Test Results.
Chen L; Reynolds C; David R; Peace Brewer A
Dig Dis Sci; 2020 Apr; 65(4):1111-1124. PubMed ID: 31529411
[TBL] [Abstract][Full Text] [Related]
4. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
5. Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children.
Seo SC; Ahn SH; Ri S; Yoon Y; Byeon JH; Kim SH; Yoon W; Yoo Y
Asian Pac J Allergy Immunol; 2018 Jun; 36(2):82-87. PubMed ID: 28938841
[TBL] [Abstract][Full Text] [Related]
6. Infant Colic Represents Gut Inflammation and Dysbiosis.
Rhoads JM; Collins J; Fatheree NY; Hashmi SS; Taylor CM; Luo M; Hoang TK; Gleason WA; Van Arsdall MR; Navarro F; Liu Y
J Pediatr; 2018 Dec; 203():55-61.e3. PubMed ID: 30177353
[TBL] [Abstract][Full Text] [Related]
7. Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.
Tews HC; Elger T; Gunawan S; Fererberger T; Sommersberger S; Loibl J; Huss M; Liebisch G; Müller M; Kandulski A; Buechler C
Lipids Health Dis; 2023 Oct; 22(1):164. PubMed ID: 37789460
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.
Ashorn S; Honkanen T; Kolho KL; Ashorn M; Välineva T; Wei B; Braun J; Rantala I; Luukkaala T; Iltanen S
Inflamm Bowel Dis; 2009 Feb; 15(2):199-205. PubMed ID: 18618670
[TBL] [Abstract][Full Text] [Related]
9. Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance.
Munjoma PT; Chandiwana P; Wyss J; Mazhandu AJ; Jordi SBU; Gutsire R; Katsidzira L; Yilmaz B; Misselwitz B; Duri K
Front Immunol; 2023; 14():1280262. PubMed ID: 38045684
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children.
Chen CC; Huang JL; Chang CJ; Kong MS
J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):541-7. PubMed ID: 22699836
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
Kolho KL; Raivio T; Lindahl H; Savilahti E
Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
[TBL] [Abstract][Full Text] [Related]
13. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.
Shaw KA; Bertha M; Hofmekler T; Chopra P; Vatanen T; Srivatsa A; Prince J; Kumar A; Sauer C; Zwick ME; Satten GA; Kostic AD; Mulle JG; Xavier RJ; Kugathasan S
Genome Med; 2016 Jul; 8(1):75. PubMed ID: 27412252
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
Hradsky O; Ohem J; Mitrova K; Durilova M; Kotalova R; Nevoral J; Kolho KL; Bronsky J
Clin Lab; 2014; 60(12):1993-2000. PubMed ID: 25651733
[TBL] [Abstract][Full Text] [Related]
15. Chronic Psychosocial Stress and Gut Health in Children: Associations With Calprotectin and Fecal Short-Chain Fatty Acids.
Michels N; Van de Wiele T; De Henauw S
Psychosom Med; 2017 Oct; 79(8):927-935. PubMed ID: 27787408
[TBL] [Abstract][Full Text] [Related]
16. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6.
Orivuori L; Mustonen K; de Goffau MC; Hakala S; Paasela M; Roduit C; Dalphin JC; Genuneit J; Lauener R; Riedler J; Weber J; von Mutius E; Pekkanen J; Harmsen HJM; Vaarala O;
Clin Exp Allergy; 2015 May; 45(5):928-939. PubMed ID: 25758537
[TBL] [Abstract][Full Text] [Related]
17. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease.
Schwiertz A; Spiegel J; Dillmann U; Grundmann D; Bürmann J; Faßbender K; Schäfer KH; Unger MM
Parkinsonism Relat Disord; 2018 May; 50():104-107. PubMed ID: 29454662
[TBL] [Abstract][Full Text] [Related]
18. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum.
Klingberg E; Carlsten H; Hilme E; Hedberg M; Forsblad-d'Elia H
Scand J Gastroenterol; 2012 Apr; 47(4):435-44. PubMed ID: 22229862
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.
Kostakis ID; Cholidou KG; Vaiopoulos AG; Vlachos IS; Perrea D; Vaos G
Dig Dis Sci; 2013 Feb; 58(2):309-19. PubMed ID: 22899243
[TBL] [Abstract][Full Text] [Related]
20. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
